Proactive Investors - Run By Investors For Investors

ECO Animal Health signs poultry vaccine development licencing deal with Ghent University

The vaccine is for Clostridium perfringens, a bacterium which normally inhabits the gastrointestinal system but when predisposing triggers are present, specific strains can cause necrotic enteritis with major consequences for bird health and growth
Poultry
In a note to clients, analysts at Peel Hunt said: “This continues the company's expansion of a vaccine development programme
A subsidiary of ECO Animal Health Group PLC (LON:EAH) has entered a worldwide exclusive development and licensing deal with Ghent University (UGA)  to further develop, register and commercialise a Clostridium perfringens vaccine for poultry.
 
The group said the deal allows it to further develop, register and commercialize a vaccine for poultry based on antigens co-developed by Prof. Filip Van Immerseel (Laboratory of Bacteriology, Faculty of Veterinary Medicine Ghent University) and Prof. Rick Titball (College of Life and Environmental Sciences, University of Exeter). Clostridium perfringens is a bacterium which normally inhabits the gastrointestinal system but when predisposing triggers are present, specific strains can cause necrotic enteritis with major consequences for bird health and growth.
 
 
Peter Lawrence, Non-Executive Chairman of ECO Animal Health commented: “Necrotic enteritis can result in a significant reduction in body weight and increase in feed conversion rate when compared with healthy broilers”.
 
In a note to clients, analysts at Peel Hunt said: “This continues the company's expansion of a vaccine development programme. The shares are trading on an ex-cash PE of 21.7x.”
 
Shares in the AIM-listed pharmaceutical firm were unmoved in early morning trading.
 
View full EAH profile View Profile

Eco Animal Health Group Plc Timeline

Related Articles

salmon
January 30 2019
Long-term fundamentals remain firmly in the seafood specialist's favour.
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use